MediWound Ltd MDWD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MDWD is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $17.66
- Day Range
- $17.65–18.50
- 52-Week Range
- $7.10–18.75
- Bid/Ask
- $18.15 / $18.24
- Market Cap
- $173.13 Mil
- Volume/Avg
- 73,119 / 77,021
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 8.80
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 88
- Website
- https://www.mediwound.com
Comparables
Valuation
|
Metric
|
MDWD
|
BLU
|
NVCT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 5.32 | 5.83 | 9.29 |
Price/Sales | 8.80 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
MDWD
BLU
NVCT
Financial Strength
|
Metric
|
MDWD
|
BLU
|
NVCT
|
|---|---|---|---|
Quick Ratio | 4.24 | 32.13 | 2.74 |
Current Ratio | 4.59 | 33.42 | 2.75 |
Interest Coverage | −19.78 | −1,125.80 | — |
Quick Ratio
MDWD
BLU
NVCT
Profitability
|
Metric
|
MDWD
|
BLU
|
NVCT
|
|---|---|---|---|
Return on Assets (Normalized) | −18.38% | −21.75% | −85.22% |
Return on Equity (Normalized) | −40.47% | −26.24% | −115.93% |
Return on Invested Capital (Normalized) | −41.40% | −24.47% | −120.14% |
Return on Assets
MDWD
BLU
NVCT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lywqfxpkv | Tfr | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Fcrwztz | Xlhlxpn | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Txzlzhmt | Qnkzgg | $97.8 Bil | |
MRNA
| Moderna Inc | Lhpzdhl | Gmfq | $41.3 Bil | |
ARGX
| argenx SE ADR | Yfzlnygm | Jbgl | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Grcywlz | Mvbp | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mmqktgb | Kyckgd | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vjxdmjpv | Dtmjlj | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Skszjdhthd | Zdlymm | $12.5 Bil | |
INCY
| Incyte Corp | Fzrqvrm | Pmzls | $11.6 Bil |